Prostate Cancer

An online tool is designed to help men with prostate or other types of cancer deal with sexual dysfunction and other common side effects of treatment.

Photographer Bill Aron discusses his book.

Photographer Bill Aron tells his prostate cancer story.

Clinical development of prostate cancer vaccines is moving forward.

When the USPSTF issued its recommendation against PSA testing, urologists nationwide, myself included, warned about the possible public health repercussions that could ensue. Our fears have materialized, and much sooner than anticipated.

Adding the chemotherapy docetaxel to standard combination hormonal and radiation therapy boosted survival rates in patients with high-risk localized prostate cancer, according to a study.

Data from a new report that shows compelling information on physicians who use Twitter, types of cancer, and ways to assess integrity.

The combination of multiparametric MRI with a fusion-guided biopsy (MRI plus ultrasound) was more effective at detecting aggressive prostate cancer compared with either procedure alone.

Although use of robotic surgery for prostate cancer has surpassed open surgical procedures in number, the impact of this approach on patient quality of life has not been well-studied.

The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.

Surgery has its side effects, says radiation oncologist Richard Stock, including possible incontinence and sexual dysfunction. While radiation is less invasive, it does have its own side effects.

Treatment with Xtandi reduced the risk of progression by 76 percent compared with bicalutamide in men with castration-resistant prostate cancer, according to topline results from the phase 2 STRIVE study.

The FDA has updated the label for Zytiga plus prednisone to include data that detailed a significant prolongation in overall survival for Zytiga versus placebo in chemotherapy-naive men with metastatic castration-resistant prostate cancer.

Two studies investigating Xtandi in men with early-stage metastatic castration-resistant prostate cancer (mCRPC) further confirmed the overall survival (OS) and progression-free survival (PFS) benefit of the agent over placebo, according to two recent studies.

Leonard Gomella, chair of the urology department and director of the Kimmel Cancer Center Network, explains active surveillance when it comes to a prostate cancer diagnosis.

The continuing contentious debate about screening for prostate cancer remains top of mind among the public and lay press.

Emmanuel S. Antonarakis explains data looking at AR-V7 and response to taxane therapy in men with metastatic castration-resistant prostate cancer.

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared with those without a history of testicular cancer.

Bill that would create a National Prostate Cancer Council—charged with creating a plan for the screening, diagnosis and monitoring of prostate cancer—was introduced Jan. 21 by Sen. Barbara Boxer.

ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer patients with localized disease to receive high quality care from specialists and primary care physicians.

Recent results from the phase 2 TERRAIN trial showed Xtandi increased progression-free survival by nearly 10 months compared with Casodex in patients with metastatic castration-resistant prostate cancer.

Raoul Concepcion, a urologist with Urology Associates in Nashville, Tenn., explains Gleason score and Gleason grade as it relates to a prostate cancer diagnosis.

Men undergoing prostate cancer treatment should give special attention to ensuring good pelvic floor strength in order to reduce side effects of treatment and maximize urinary and sexual function.

One-third of men over 70 years of age who undergo radical prostatectomy for prostate cancer and then experience biochemical recurrence have no need for salvage treatment, according to a recent study.

Prostate cancer drug Xtandi, as well as the blood cancer drug Imbruvica, may help additional patients with these cancers.